Abstract
The development of lymphomas and leukemias is frequently caused by chromosomal translocations that deregulate cellular pathways of differentiation, proliferation or survival. The molecules that are involved in these aberrations provide rational targets for selective drug therapies. Recently, several disease specific translocations have been identified in human MALT lymphoma. These aberrations either upregulate the expression of BCL10 or MALT1 or induce the formation of API2-MALT1 fusion proteins. Genetic and biochemical experiments identified BCL10 and MALT1 as central components of an oligomerization - ubiquitinylation – phosphorylation cascade that activates the transcription factor NF-κB in response to antigen receptor ligation. Deregulation of the signaling cascade is directly associated with antigen independent MALT lymphoma growth. Here we provide an overview of the physiological and pathological functions of BCL10 / MALT1 signal transduction and discuss the potential of this pathway as a drug target.
Keywords: Lymphoma, Malt1, Bcl10, API2-MALT1, NF-κB, antigen receptor, chromosomal translocation, fusion protein
Current Drug Targets
Title: The Bcl10 / Malt1 Signaling Pathway as a Drug Target in Lymphoma
Volume: 7 Issue: 10
Author(s): P. Jost, C. Peschel and J. Ruland
Affiliation:
Keywords: Lymphoma, Malt1, Bcl10, API2-MALT1, NF-κB, antigen receptor, chromosomal translocation, fusion protein
Abstract: The development of lymphomas and leukemias is frequently caused by chromosomal translocations that deregulate cellular pathways of differentiation, proliferation or survival. The molecules that are involved in these aberrations provide rational targets for selective drug therapies. Recently, several disease specific translocations have been identified in human MALT lymphoma. These aberrations either upregulate the expression of BCL10 or MALT1 or induce the formation of API2-MALT1 fusion proteins. Genetic and biochemical experiments identified BCL10 and MALT1 as central components of an oligomerization - ubiquitinylation – phosphorylation cascade that activates the transcription factor NF-κB in response to antigen receptor ligation. Deregulation of the signaling cascade is directly associated with antigen independent MALT lymphoma growth. Here we provide an overview of the physiological and pathological functions of BCL10 / MALT1 signal transduction and discuss the potential of this pathway as a drug target.
Export Options
About this article
Cite this article as:
Jost P., Peschel C. and Ruland J., The Bcl10 / Malt1 Signaling Pathway as a Drug Target in Lymphoma, Current Drug Targets 2006; 7 (10) . https://dx.doi.org/10.2174/138945006778559256
DOI https://dx.doi.org/10.2174/138945006778559256 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Quest for Novel Biomarkers in Early Diagnosis of Diabetic Neuropathy
Current Proteomics The Ubiquitin-Proteasome System as a Prospective Molecular Target for Cancer Treatment and Prevention
Current Protein & Peptide Science MicroRNAs: Tiny but Not Trivial
Current Genomics Supertargeted Chemistry: Identifying Relationships Between Molecular Structures and their Sub-Cellular Distribution
Current Topics in Medicinal Chemistry Exposure of B Cell Chronic Lymphocytic Leukemia (B-CLL) Cells to Nutlin-3 Induces a Characteristic Gene Expression Profile, which Correlates with Nutlin-3-Mediated Cytotoxicity (Supplementry Table)
Current Cancer Drug Targets Click Chemistry, A Potent Tool in Medicinal Sciences
Current Medicinal Chemistry Glioblastoma Multiforme Imaging: The Role of Nuclear Medicine
Current Radiopharmaceuticals Therapeutic Potential of Coagonists of Glucagon and GLP-1
Cardiovascular & Hematological Agents in Medicinal Chemistry Exploring Polypharmacology in Drug Discovery and Repurposing Using the CANDO Platform
Current Pharmaceutical Design Microbes, Immunity and Multiple Sclerosis
Current Immunology Reviews (Discontinued) Targeting of Cancer-Related Proteins with PNA Oligomers
Current Cancer Drug Targets Lipid Nanoparticles to Deliver miRNA in Cancer
Current Pharmaceutical Biotechnology Growth Factors, Cytokines and Dendritic Cell Development
Current Pharmaceutical Design Cancer T Cell Immunotherapy with Bispecific Antibodies and Chimeric Antigen Receptors
Recent Patents on Anti-Cancer Drug Discovery Targeted Drug Delivery: Trends and Perspectives
Current Drug Delivery Disposition of Vorinostat, A Novel Histone Deacetylase Inhibitor and Anticancer Agent, in Preclinical Species
Drug Metabolism Letters Epigenetic Targeting of Platinum Resistant Testicular Cancer
Current Cancer Drug Targets Novel Treatment of Acute Promyelocytic Leukemia: As<sub>2</sub>O<sub>3</sub>, Retinoic Acid and Retinoid Pharmacology
Current Pharmaceutical Biotechnology Novel Analogues of CC-1065 and the Duocarmycins for the Use in Targeted Tumour Therapies
Anti-Cancer Agents in Medicinal Chemistry HSF1, A Versatile Factor in Tumorogenesis
Current Molecular Medicine